Should I buy or sell Precision BioSciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DTIL shares. View DTIL analyst ratings or view top-rated stocks .

What is Precision BioSciences' stock price target for 2024?

2 equities research analysts have issued 1 year target prices for Precision BioSciences' shares. Their DTIL share price targets range from $60.00 to $60.00. On average, they expect the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 359.4% from the stock's current price. View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts .

How have DTIL shares performed in 2024?

Precision BioSciences' stock was trading at $10.95 at the beginning of the year. Since then, DTIL stock has increased by 19.3% and is now trading at $13.06. View the best growth stocks for 2024 here .

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 288,900 shares, an increase of 62.3% from the March 15th total of 178,000 shares. Based on an average daily volume of 139,500 shares, the short-interest ratio is presently 2.1 days. Currently, 8.0% of the shares of the stock are sold short. View Precision BioSciences' Short Interest .

When is Precision BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our DTIL earnings forecast .

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) posted its earnings results on Wednesday, November, 10th. The company reported ($5.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($17.70) by $12.00. The company earned $24.04 million during the quarter, compared to analyst estimates of $8.54 million. Precision BioSciences had a negative trailing twelve-month return on equity of 204.66% and a negative net margin of 125.84%. During the same quarter in the prior year, the company earned ($15.00) EPS.

What ETF holds Precision BioSciences' stock?

Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

When did Precision BioSciences' stock split?

Shares of Precision BioSciences reverse split on Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com . Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT) , Sorrento Therapeutics (SRNE) , Alector (ALEC) , Kaleido Biosciences (KLDO) , Gossamer Bio (GOSS) , Micron Technology (MU) , Homology Medicines (FIXX) , Heron Therapeutics (HRTX) , Inovio Pharmaceuticals (INO) and Invitae (NVTA) .

When did Precision BioSciences IPO?

Precision BioSciences (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free DTIL Stock Alerts

$13.06

-1.06 (-7.51%)

(As of 04/15/2024 ET)

Compare

Today's Range: $12.58
▼
$14.39
50-Day Range: $10.91
▼
$18.56
52-Week Range: $8.25
▼
$28.44

Volume: 115,048 shs
Average Volume: 127,013 shs
Market Capitalization: $90.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $60.00

Get Precision BioSciences alerts:

Precision BioSciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 359.4% Upside
$60.00 Price Target
Short Interest: Bearish
8.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.99
Upright™ Environmental Score
News Sentiment: 0.63
Based on 4 Articles This Week
Insider Trading: Selling Shares
$64,854 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.93) to ($2.87) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

221st out of 928 stocks

Biological Products, Except Diagnostic Industry

28th out of 156 stocks

3.5

Analyst's Opinion

Consensus Rating
Precision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Precision BioSciences has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.03% of the float of Precision BioSciences has been sold short.
Short Interest Ratio / Days to Cover
Precision BioSciences has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Precision BioSciences has recently increased by 62.30%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Precision BioSciences does not currently pay a dividend.
Dividend Growth
Precision BioSciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Precision BioSciences has received a 72.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Precision BioSciences is -0.99.

2.6

News and Social Media Coverage

News Sentiment
Precision BioSciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Precision BioSciences this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
10 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Precision BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,854.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Precision BioSciences is held by insiders.
Percentage Held by Institutions
Only 37.99% of the stock of Precision BioSciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Precision BioSciences are expected to grow in the coming year, from ($3.93) to ($2.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Precision BioSciences is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Precision BioSciences is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Precision BioSciences has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Precision BioSciences Stock (NASDAQ:DTIL)

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DTIL Stock News Headlines

April 12, 2024 | americanbankingnews.com

Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Up 62.3% in March

April 11, 2024 | investing.com

Precision BioSciences Inc (DTIL)

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

April 9, 2024 | yahoo.com

Precision Air & Plumbing offers tips on buying a new AC unit before summer hits

April 9, 2024 | forbes.com

Precision Diagnostics Can Save Money In Healthcare: What’s Holding Them Back?

April 2, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know

March 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Precision BioSciences on Promising Gene Editing Prospects and Strong Financials

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Precision BioSciences as Milestones in Gene Editing Technology Loom

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

March 27, 2024 | investorplace.com

DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023

March 27, 2024 | markets.businessinsider.com

Precision BioSciences Inc Q4 Loss decreases, but misses estimates

March 27, 2024 | businesswire.com

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

March 26, 2024 | benzinga.com

Earnings Preview: Precision BioSciences

March 26, 2024 | msn.com

Precision BioSciences Q4 Earnings Preview

March 20, 2024 | businesswire.com

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

March 19, 2024 | baystreet.ca

Precision BioSciences Flat on New Product Development

March 19, 2024 | businesswire.com

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

March 18, 2024 | finance.yahoo.com

DNAnexus to Showcase the Power of High-Value Multi-Omics Data at the Precision Medicine in IBD Summit

March 15, 2024 | yahoo.com

Fender teams up with Fornite to bring its Stratocaster and Precision Bass to the digital realm

March 14, 2024 | bizjournals.com

Machining company Thomas Precision sells vacant Union County facility

March 12, 2024 | msn.com

The Anova Precision Cooker Nano sous vide machine drops to a record low of $60

March 7, 2024 | finance.yahoo.com

Precision BioSciences, Inc. (PBS0.F)

March 6, 2024 | businesswire.com

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

March 4, 2024 | bizjournals.com

Durham gene editing firm raising $40M for Hepatitis B treatment

March 2, 2024 | investing.com

Precision BioSciences announces public stock offering

March 1, 2024 | marketwatch.com

Precision BioSciences Shares Slide Premarket After Stock Offering

March 1, 2024 | msn.com

Cardiff Oncology, DermTech, Precision Biosciences among healthcare movers

See More Headlines

Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:DTIL
CUSIP: N/A
CIK: 1357874
Web: www.precisionbiosciences.com
Phone: (919) 314-5512
Fax: N/A
Employees: 115
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $60.00
High Stock Price Target: $60.00
Low Stock Price Target: $60.00
Potential Upside/Downside: +359.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($16.0720)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-61,320,000.00
Net Margins: -125.84%
Pretax Margin: -87.28%
Return on Equity: -204.66%
Return on Assets: -35.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.73
Quick Ratio: 2.73

Sales & Book Value

Annual Sales: $48.73 million
Price / Sales: 1.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.53 per share
Price / Book: 2.88

Miscellaneous

Outstanding Shares: 6,920,000
Free Float: 6,563,000
Market Cap: $90.38 million
Optionable: Optionable
Beta: 1.53

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Michael Amoroso (Age 45)
President, CEO & Director
Comp: $979.04k
Mr. John Alexander Kelly R.Ph. (Age 57)
CFO & Principal Accounting Officer
Comp: $623.58k
Mr. Dario Scimeca (Age 48)
General Counsel & Secretary
Comp: $576.43k
Dr. Jefferson J. Smith Ph.D. (Age 51)
Co-Founder & Chief Research Officer
Mei Burris
Director of Investor Relations & Finance
Mr. Bruce Stevens
Vice President of Quality & Compliance
Maurissa Messier
Senior Director of Corporate Communications
Ms. Juli Blanche
Chief People Officer
Mr. Garrett Gincley
Head of Manufacturing
Dr. Alan F. List M.D. (Age 69)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DTIL Stock Analysis - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DTIL shares.
View DTIL analyst ratings or view top-rated stocks.
What is Precision BioSciences' stock price target for 2024?: 2 equities research analysts have issued 1 year target prices for Precision BioSciences' shares. Their DTIL share price targets range from $60.00 to $60.00. On average, they expect the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 359.4% from the stock's current price.
View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts.
How have DTIL shares performed in 2024?: Precision BioSciences' stock was trading at $10.95 at the beginning of the year. Since then, DTIL stock has increased by 19.3% and is now trading at $13.06.
View the best growth stocks for 2024 here.
Are investors shorting Precision BioSciences?: Precision BioSciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 288,900 shares, an increase of 62.3% from the March 15th total of 178,000 shares. Based on an average daily volume of 139,500 shares, the short-interest ratio is presently 2.1 days. Currently, 8.0% of the shares of the stock are sold short.
View Precision BioSciences' Short Interest.
When is Precision BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our DTIL earnings forecast.
How were Precision BioSciences' earnings last quarter?: Precision BioSciences, Inc. (NASDAQ:DTIL) posted its earnings results on Wednesday, November, 10th. The company reported ($5.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($17.70) by $12.00. The company earned $24.04 million during the quarter, compared to analyst estimates of $8.54 million. Precision BioSciences had a negative trailing twelve-month return on equity of 204.66% and a negative net margin of 125.84%. During the same quarter in the prior year, the company earned ($15.00) EPS.

What ETF holds Precision BioSciences' stock?: Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.
When did Precision BioSciences' stock split?: Shares of Precision BioSciences reverse split on Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What is Matt Kane's approval rating as Precision BioSciences' CEO?: 12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Precision BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).
When did Precision BioSciences IPO?: Precision BioSciences (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.
How do I buy shares of Precision BioSciences?: Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DTIL) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Precision BioSciences (DTIL) Stock Price, News & Analysis

Precision BioSciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Precision BioSciences Stock (NASDAQ:DTIL)

DTIL Stock Price History

DTIL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DTIL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™